Presentations
The following presentations were delivered by MVI staff at various malaria-related conferences and events. They are listed chronologically, beginning with the most recent.
Ten years of PDPs: Achievements, lessons learned, & challenges for the future
(942 KB PDF)
November 2, 2009
Ashley Birkett's presentation, delivered at the Fifth Multilateral Initiative on Malaria Conference in Nairobi, Kenya, gives an overview of MVI and its history as a product development partnership.
PATH Malaria Vaccine Initiative: current status, future plans (1,023 KB PDF)
June 5, 2008
Christian Loucq's presentation, delivered at a meeting with the GAVI Alliance, provides an overview of MVI, MVI’s role in the global vaccine development arena, and how MVI’s current vaccine portfolio and future plans will affect research and development efforts worldwide.
Malaria vaccine pipeline: perspectives and challenges (1,125 KB PDF)
June 3, 2008
Carla Botting's presentation, delivered at the 2008 Vaccine Congress in Singapore, discusses the malaria disease burden, challenges facing the field of malaria vaccine development, status of malaria vaccine development on a global scale, and MVI’s vaccine development strategy.
Planning the introduction of a malaria vaccine: the Regional Decision-Making Framework (282 KB PDF)
April 25, 2008
Antoinette Ba-Nguz's presentation, delivered in Lilongwe, Malawi, provides an overview of the Decision-Making Framework, explains the importance of early preparation to adopt an eventual malaria vaccine, and describes the actions required to implement the framework on a regional and national level.
Investment case for malaria vaccines (111 KB PDF)
May 31, 2006
Alan Brooks delivered this presentation at the 2006 Global Health Council Conference held in Washington, DC. It provides an in-depth look at the need and required steps for building a public- and private-sector investment case for health interventions, specifically malaria vaccines.
Market assessment for malaria vaccines (2,058 KB PDF)
January 19, 2005
This presentation, developed by the Boston Consulting Group, provides an in-depth look at the global market assessment of demand for malaria vaccines. Although we are likely years away from a licensed malaria vaccine, the malaria community requires improved information for decision-making. While the target population for a malaria vaccine is theoretically large—nearly 40 percent of the world’s population is at risk—the number of those who could pay for or would use a particular malaria vaccine is likely substantially lower. Understanding the components and dynamics of actual demand is critical to addressing current pressing issues in malaria vaccine development, and to ensuring that the introduction of a vaccine results in early, widespread use.
Harnessing medical technology to fight global diseases: where science and advocacy meet (827 KB PDF)
June 26, 2003
Melinda Moree's presentation, delivered at the BIO 2003 Conference, is designed to update biotech companies on progress and opportunities for creating new tools to prevent AIDS, TB, and malaria. This workshop provided overviews on the state of research and development of HIV vaccines and microbicides, and vaccines for prevention of TB and malaria. It also gave an update on legislative and policy initiatives to harness expertise in pharmaceutical and biotech companies toward the accelerated development of these technologies.
Malaria vaccines 2002 (505 KB PDF)
November 21, 2002
Ripley Ballou delivered the malaria vaccine plenary at the 3rd Multilateral Initiative on Malaria Pan African Conference on Malaria. With his permission, his presentation on the current status of malaria vaccine development is available here.
